Inicia sesión Registrate Mi Biblioteca biblioteca abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de artículos sobre Trastornos del Movimiento clasificados según los 11 tipos establecidos por la International Parkinson & Movement Disorder Society.

Tratamiento no farmacológico

364 ARTíCULOS , VIENDO DEL 346 AL 360

PUBMED

Bapineuzumab and solanezumab for Alzheimer's disease: is the 'amyloid cascade hypothesis' still alive?

Tayeb HO, Murray ED, Price BH, Tarazi FI.

Expert Opin Biol Ther. 2013 Jul;13(7):1075-84. doi: 10.1517/14712598.2013.789856. Epub 2013 Apr 10.

0

0

0

PUBMED

Alzheimer's disease, dementia, mild cognitive impairment and the menopause: a 'window of opportunity'?

Davey DA.

Womens Health (Lond). 2013 May;9(3):279-90. doi: 10.2217/whe.13.22.

0

0

0

PUBMED

Mitochondrial filamentation: a therapeutic target for neurodegeneration and aging

Gosalvez M.

Am J Alzheimers Dis Other Demen. 2013 Aug;28(5):423-6. doi: 10.1177/1533317513494451.

0

0

0

PUBMED

Acetylcholinesterase inhibitors as Alzheimer therapy: from nerve toxins to neuroprotection

Singh M, Kaur M, Kukreja H, Chugh R, Silakari O, Singh D.

Eur J Med Chem. 2013;70:165-88. doi: 10.1016/j.ejmech.2013.09.050. Epub 2013 Oct 6.

0

0

0

PUBMED

Dual inhibitors of monoamine oxidase and cholinesterase for the treatment of Alzheimer disease

Yáñez M, Viña D.

Curr Top Med Chem. 2013;13(14):1692-706. doi: 10.2174/15680266113139990120.

0

0

0

PUBMED

Phenylbutyrate is a multifaceted drug that exerts neuroprotective effects and reverses the Alzheimer´s disease-like phenotype of a commonly used mouse model

Cuadrado-Tejedor M, Ricobaraza AL, Torrijo R, Franco R, Garcia-Osta A.

Curr Pharm Des. 2013;19(28):5076-84. doi: 10.2174/1381612811319280006.

0

0

0

PUBMED

Adherence to cholinesterase inhibitors in Alzheimer's disease: a review

Brady R, Weinman J.

Dement Geriatr Cogn Disord. 2013;35(5-6):351-63. doi: 10.1159/000347140. Epub 2013 Apr 19.

0

0

0

PUBMED

Alzheimer disease therapy--moving from amyloid-β to tau

Giacobini E, Gold G.

Nat Rev Neurol. 2013 Dec;9(12):677-86. doi: 10.1038/nrneurol.2013.223. Epub 2013 Nov 12.

0

0

0

PUBMED

[Cholesterol inhibitor and memantine in symptomatic dementia therapy]

Rodda J, Carter J.

Praxis (Bern 1994). 2013 Feb 27;102(5):293-300; discussion 298-9. doi: 10.1024/1661-8157/a001209.

0

0

0

PUBMED

Inhibitors of BACE for treating Alzheimer's disease: a fragment-based drug discovery story

Stamford A, Strickland C.

Curr Opin Chem Biol. 2013 Jun;17(3):320-8. doi: 10.1016/j.cbpa.2013.04.016. Epub 2013 May 14.

0

0

0

PUBMED

A brief review on studies of Alzheimer's disease in China: its mechanism, imaging and therapy

Shi H, Wang Z.

Sci China Life Sci. 2013 Dec;56(12):1142-4. doi: 10.1007/s11427-013-4566-1. Epub 2013 Dec 5.

0

0

0

PUBMED

Multifunctional tacrine derivatives in Alzheimer's disease

Minarini A, Milelli A, Simoni E, Rosini M, Bolognesi ML, Marchetti C, Tumiatti V.

Curr Top Med Chem. 2013;13(15):1771-86. doi: 10.2174/15680266113139990136.

0

0

0

PUBMED

Progress of "Current Alzheimer Research" and future direction

Lahiri DK.

Curr Alzheimer Res. 2013 Jan;10(1):1-3. doi: 10.2174/1567205011310010001.

0

0

0

PUBMED

Who is that stranger in the mirror? The mirror experience for elderly patients with dementia

Kelsick JR, Freysteinson WM.

Holist Nurs Pract. 2013 Sep-Oct;27(5):268-72. doi: 10.1097/HNP.0b013e31829b924a.

0

0

0

PUBMED

[Alzheimer's disease and depression]

Mizukami K.

Seishin Shinkeigaku Zasshi. 2013;115(11):1122-6.

0

0

0

Comentarios

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neuroacademy